Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer
|First Received Date ICMJE||December 14, 2005|
|Last Updated Date||January 15, 2014|
|Start Date ICMJE||October 2004|
|Primary Completion Date||April 2009 (final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||The purpose of this study is to determine the safety of using a treatment called transimmunization in addition to standard therapy (radiation) in the treatment of lung cancer. [ Time Frame: 1-2 yrs ] [ Designated as safety issue: No ]|
|Original Primary Outcome Measures ICMJE
||The purpose of this study is to determine the safety of using a treatment called transimmunization in addition to standard therapy (radiation) in the treatment of lung cancer.|
|Change History||Complete list of historical versions of study NCT00265603 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE||Not Provided|
|Original Secondary Outcome Measures ICMJE||Not Provided|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer|
|Official Title ICMJE||Phase 1 Toxicity/Feasibility Study: Combined Modality Treatment With Transimmunization for Non-Small Cell Lung Cancer|
|Brief Summary||The purpose of this study is to determine the safety of using a treatment called transimmunization in addition to standard therapy (radiation) in the treatment of lung cancer. Transimmunization is a treatment of the blood designed to boost the immune response against lung cancer. Transimmunization uses a device called a UVAR-XTS instrument, to remove a portion of blood, part of which is returned, and part of which is incubated overnight before being returned to the bloodstream the next day.|
Lung cancer is the leading cause of cancer death in both men and women in the United States. It is estimated that there are over 170,000 new cases of lung cancer in the United States and over 150,000 deaths annually. Surgical excision is currently the treatment of choice for patients with operable non-small cell lung cancer (NSCLC). However, only a minority of patients present with early stage, surgically resectable disease. Most patients present with advanced disease confined to the chest, but not surgically resectable (Stage IIIB), or metastatic disease (Stage IV). Conventional treatment for stage IIIB NSCLC is concurrent or sequential radiation therapy and chemotherapy, while standard treatment for stage IV disease is chemotherapy therapy alone, with radiation therapy for palliative adjunctive treatment. Currently, five-year survival rates for patients with Stage IIIB and IV disease, treated or untreated, is less than 15%. We propose herein a Phase I trial to assess the safety of Transimmunization as a component of combined modality treatment for stage IIIB or IV NSCLC by incorporating this immunotherapy with radiotherapy.
Extracorporeal photochemotherapy (ECP), or photopheresis, was originally introduced for the management of patients with cutaneous T cell lymphoma (CTCL). In the fifteen years since it became the first FDA approved tumor-targeting selective immunotherapy for the treatment of any cancer, it has induced partial responses in a majority of the erythrodermic CTCL patients with residual immunocompetence to whom it has been administered (in more than 150 centers, more than 250,000 times) throughout the US and Europe. Although combined modality data are limited for the use of ECP with radiation, one study has demonstrated disease free survival (DFS) and cause specific survival (CSS) advantage (after adjusting for B1 status and stage) for patients with erythrodermic mycosis fungoides who received a combination of ECP and total skin electron beam therapy (TSEBT) compared to TSBET without ECP. In a subset of these patients, persistent complete remissions have resulted from the therapy, suggesting that powerful and clinically relevant cytotoxic anti-tumor immune responses had been initiated. ECP has been distinguished from other forms of anti-cancer immunotherapy by both its efficacy and safety, but its evolution has been limited by the mystery of its mechanism. Recently, the key cellular components of ECP's efficacy, namely the simultaneous induction of apoptosis of malignant T cells and monocyte-to-dendritic cell (DC) conversion, have been recognized. Repetitive cycles of leukocyte adherence to and dissociation from the plastic (i.e. acrylic) faces of the ECP flow system device lead to the synchronous differentiation, within a single day, of processed monocytes into an extraordinarily large number (250 million) of immature DCs capable of internalizing apoptotic malignant cells and processing the expressed tumor antigens. This engineered phenomenon may be a mimicking of the normal conversion of monocytes to DCs as they insinuate themselves between endothelial cells to enter interstitial spaces.
Recently, we have found that overnight co-incubation of the two populations of induced cells, prior to their re-infusion, allows for more efficient cell-to-cell contact and processing of the apoptotic malignant T cells by the newly formed DCs, thus providing a rich source of tumor-loaded DCs in which all available tumor antigens are likely processed without the need to chemically isolate them or know their identity. We have termed the resulting transfer of immunizing tumor antigens to DC capable of stimulating specific anti-cancer immune responses "Transimmunization."
By incubating a patient's treated cells overnight, rather than returning them within two hours of photopheresis, as has been standard, we are able to increase the yield of dendritic cells. Rather than expose these DCs to malignant cells in vitro (in the overnight culture) as occurs in the treatment of CTCL, we propose to intravenously return the DCs to the patient-after overnight incubation in an effort to drive dendritic cell maturation-while the patient is undergoing a course of radiation therapy for NSCLC. Radiation therapy induces a cellular death via several mechanisms-including Apoptosis. Since intravenous return of the ECP-induced DCs would first (via the right heart) passage through the lung microvasculature, it is theorized that the DCs may gain access to the tumor. Direct anti-tumor effects by the DCs, as well as uptake of tumor cells/fragments and subsequent inductions of an anti-tumor response are potential beneficial consequences of the treatment.
The treatment involves the extracorporeal exposure of leukapheresed leukocytes to ultraviolet A activated 8-methoxypsoralen, a molecule naturally occurring in small quantities in a variety of plant products, including lime and celery. When this biologically inert furocoumarin is transiently activated by ultraviolet A energy, it is temporarily transformed into an alkylating agent which binds to pyrimidine bases of DNA. Since a single 8-MOP molecule is bivalent, cross-links between sister strands of DNA are formed, inhibiting both mitosis and gene function. It is important to note that while tumor cells will not be present in this mix (as is the case in leukemic cutaneous T cell lymphoma), and therefore will not be induced via 8-MOP/UVA exposure to undergo apoptosis, normal peripheral T cells that will be 8-MOP/UVA-induced into the apoptotic pathway are considered critical to driving monocytes to DC differentiation.
KLH (depyrogenated, endotoxin-free; Calbiochem-Novabiochem Corp., San Diego, CA) will be added at a concentration of 10 mg/ml to the DC-rich leukocyte culture prior to overnight culture. The cells will be placed in a CO2 incubator at 37° C overnight. The incubator will be committed solely to this purpose; only that patient's cells will be in it overnight; and it will be locked. The following morning, the patient's cells will be washed (i.e. centrifuged, re-suspended in 250 ml normal saline, and then centrifugated a second time) prior to being re-suspended in 250 mL of normal saline for infusion. The cells will be returned to the patient by intravenous infusion.
Side effects for standard photopheresis have been extremely limited and have required cessation of photopheresis in less than 1% of subjects. These side effects have most commonly included transient hypotension, due to the transient depletion in intravascular volume, which has been reversible on reinfusion of the blood, occasional difficulty in cannulating the antecubital vein, fever for a few hours following infusion of treated cells and elevation of serum uric acid, correctable with oral allopurinol administration. The current Phase I trial of transimmunization in the management of advanced CTCL in 26 individuals has suggested improved potency over conventional photopheresis, while maintaining the same excellent safety profile. As with its antecedent photopheresis, remarkably few adverse reactions have been experienced with transimmunization, and none of the subjects in the Phase I trial experienced limiting toxicity or required cessation of therapy.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 1|
|Study Design ICMJE||Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Condition ICMJE||Non-Small Cell Lung Cancer|
|Intervention ICMJE||Procedure: Extracorporeal Photochemotherapy With Transimmunization
The photopheresis apparatus and procedure will be identical to that currently used. Patients will receive intravenous 8-MOP (UVADEX®) directly into the photopheresis apparatus, to yield a concentration of 50-200 ng/ml of drug. The blood will be leukapheresed to obtain a buffy coat and will then be passed through the contiguous closed circuit ultraviolet A exposure device, delivering the desired 1-2 joules/cm2 of ultraviolet A energy. In this manner 2-4 molecules of 8-MOP will be induced to bind covalently to thymines of the leukocyte DNA. At that point, the single variation from the standard treatment will be initiated. Instead of returning the patient's cells and the saline to the patient, the bag will be detached from the apparatus. KLH (depyrogenated, endotoxin-free; Calbiochem-Novabiochem Corp., San Diego, CA) will be added at a concentration of 10 g/ml to the DC-rich leukocyte culture prior to overnight culture.
|Study Arm (s)||Experimental: 1 Arm
The investigators plan to have approximately 16 persons participate in the study of transimmunization. Transimmunization uses a device, called a UVAR-XTS instrument, to remove a portion of blood, part of which is returned, and part of which is incubated overnight before being returned to the bloodstream the next day
Intervention: Procedure: Extracorporeal Photochemotherapy With Transimmunization
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Terminated|
|Estimated Enrollment ICMJE||16|
|Completion Date||April 2009|
|Primary Completion Date||April 2009 (final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||18 Years and older (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT00265603|
|Other Study ID Numbers ICMJE||R04-10-009|
|Has Data Monitoring Committee||Yes|
|Plan to Share Data||Not Provided|
|IPD Description||Not Provided|
|Responsible Party||Atlantic Health System|
|Study Sponsor ICMJE||Atlantic Health System|
|Collaborators ICMJE||Not Provided|
|Information Provided By||Atlantic Health System|
|Verification Date||January 2014|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP